Shares of 10x Genomics, Inc. (NASDAQ: TXG) surged 5.08% in after-hours trading following the release of its impressive second-quarter 2025 financial results and the announcement of a strategic acquisition. The biotechnology company significantly outperformed analyst expectations, demonstrating robust growth and profitability.

10x Genomics reported quarterly earnings of $0.28 per share, drastically surpassing the analyst consensus estimate of $(0.36) by 176.71%. This represents a remarkable 187.5% improvement from the $(0.32) per share loss reported in the same period last year. The company's revenue also exceeded expectations, coming in at $172.9 million, beating the analyst consensus estimate of $139.408 million by 24.02%. This strong performance marks a 12.93% increase in sales compared to the previous year.

Adding to the positive sentiment, 10x Genomics announced its plans to acquire Scale Biosciences, a move that could potentially expand its market presence and technological capabilities. The company also provided guidance for the third quarter of 2025, projecting revenue in the range of $140 million to $144 million, indicating continued growth expectations. With a gross margin of 72% and a net income of $34.5 million for Q2, 10x Genomics has demonstrated its ability to drive both top-line growth and profitability, factors that likely contributed to the stock's after-hours rally.